Detail akcie Neurocrine Bios online

Business Summary: Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator? / (AMPA PAM) and others.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Neurocrine Biosciences, Inc revenues increased 42% to $814.5M. Net income increased from $7.9M to $197.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Equity Earnings -Before Ta increase from $30.6M (expense) to $25.3M (income), Investment income and other, net increase of 29% to $28.1M (income).